These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1844 related items for PubMed ID: 16550520

  • 21. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 22. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 23. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar 15; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 24. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.
    Clin Cancer Res; 2004 Oct 01; 10(19):6661-8. PubMed ID: 15475456
    [Abstract] [Full Text] [Related]

  • 25. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
    Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, Kan Y, Yamada H.
    Anticancer Res; 2004 Oct 01; 24(5A):2705-12. PubMed ID: 15517875
    [Abstract] [Full Text] [Related]

  • 26. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
    Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2010 Jul 01; 80(1):31-8. PubMed ID: 20206141
    [Abstract] [Full Text] [Related]

  • 27. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 28. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2001 Jan 28; 296(1):31-40. PubMed ID: 11123359
    [Abstract] [Full Text] [Related]

  • 29. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 28; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 30. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H.
    Cancer Res; 2005 Oct 15; 65(20):9501-9. PubMed ID: 16230415
    [Abstract] [Full Text] [Related]

  • 31. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 32. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 33. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 01; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 34. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
    Xu R, Dong Q, Yu Y, Zhao X, Gan X, Wu D, Lu Q, Xu X, Yu XF.
    Leuk Res; 2006 Jan 01; 30(1):17-23. PubMed ID: 16023722
    [Abstract] [Full Text] [Related]

  • 35. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.
    Mol Carcinog; 2009 Jan 01; 48(1):56-65. PubMed ID: 18506760
    [Abstract] [Full Text] [Related]

  • 36. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
    Baran Y, Oztekin C, Bassoy EY.
    Cancer Invest; 2010 Jul 01; 28(6):623-8. PubMed ID: 20307198
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A, Topaly J, Fruehauf S, Zeller WJ.
    Anticancer Res; 2006 Jul 01; 26(3A):2169-77. PubMed ID: 16827161
    [Abstract] [Full Text] [Related]

  • 39. [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
    Li JE, Sun GL, Wu YL, Wu WL.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Nov 01; 24(11):580-3. PubMed ID: 14720443
    [Abstract] [Full Text] [Related]

  • 40. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
    Silvestri R, Marfè G, Artico M, La Regina G, Lavecchia A, Novellino E, Morgante E, Di Stefano C, Catalano G, Filomeni G, Abruzzese E, Ciriolo MR, Russo MA, Amadori S, Cirilli R, La Torre F, Sinibaldi Salimei P.
    J Med Chem; 2006 Sep 21; 49(19):5840-4. PubMed ID: 16970408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 93.